Alliance Wealth Advisors LLC UT Trims Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Alliance Wealth Advisors LLC UT decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 7,137 shares of the medical research company’s stock after selling 271 shares during the period. Thermo Fisher Scientific comprises 1.0% of Alliance Wealth Advisors LLC UT’s investment portfolio, making the stock its 26th biggest holding. Alliance Wealth Advisors LLC UT’s holdings in Thermo Fisher Scientific were worth $3,713,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Rheos Capital Works Inc. increased its holdings in Thermo Fisher Scientific by 19.4% in the fourth quarter. Rheos Capital Works Inc. now owns 51,000 shares of the medical research company’s stock valued at $26,532,000 after buying an additional 8,300 shares in the last quarter. S.A. Mason LLC increased its stake in shares of Thermo Fisher Scientific by 23.3% in the 4th quarter. S.A. Mason LLC now owns 476 shares of the medical research company’s stock valued at $248,000 after purchasing an additional 90 shares in the last quarter. JB Capital LLC boosted its position in Thermo Fisher Scientific by 54.3% during the fourth quarter. JB Capital LLC now owns 6,996 shares of the medical research company’s stock worth $3,639,000 after purchasing an additional 2,462 shares in the last quarter. Abner Herrman & Brock LLC grew its holdings in Thermo Fisher Scientific by 6.4% in the fourth quarter. Abner Herrman & Brock LLC now owns 17,554 shares of the medical research company’s stock valued at $9,132,000 after purchasing an additional 1,059 shares during the period. Finally, KPP Advisory Services LLC raised its stake in shares of Thermo Fisher Scientific by 4.4% during the 4th quarter. KPP Advisory Services LLC now owns 2,823 shares of the medical research company’s stock worth $1,469,000 after buying an additional 120 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently commented on TMO. Scotiabank boosted their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a “sector perform” rating in a report on Monday. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Bernstein Bank lifted their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a report on Tuesday, October 22nd. Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Finally, TD Cowen increased their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Four analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average price target of $658.00.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 9,000 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $552.86, for a total value of $4,975,740.00. Following the completion of the sale, the chief executive officer now directly owns 14,608 shares of the company’s stock, valued at approximately $8,076,178.88. The trade was a 38.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders sold 29,000 shares of company stock valued at $15,859,540. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Down 0.7 %

Shares of NYSE:TMO opened at $593.38 on Tuesday. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88. The company has a market capitalization of $226.97 billion, a price-to-earnings ratio of 35.90, a PEG ratio of 4.06 and a beta of 0.77. The business has a 50-day moving average price of $541.37 and a 200 day moving average price of $571.18. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.29 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were issued a $0.39 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.26%. Thermo Fisher Scientific’s payout ratio is 9.44%.

Thermo Fisher Scientific declared that its board has initiated a share buyback program on Friday, November 15th that authorizes the company to buyback $4.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 2% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.